UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-42623 Lakeshore Acquisition III Corp. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-42623 Lakeshore Acquisition III Corp. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

Financial Performance - Consolidated net sales for Q1 FY 2026 increased by $223,729, or 29.0%, to $996,454 compared to $772,725 in Q1 FY 2025[147] - Consolidated net earnings for Q1 FY 2026 were $133,719, representing 13.4% of net sales, compared to $87,091, or 11.3% of net sales, in Q1 FY 2025[146] - Consolidated net sales increased by $223,729, or 29.0%, to $996,454 for Q1 FY 2026, compared to $772,725 for Q1 FY 2025[156] - Consolidated net earnings increased by $46,628, or 53.5%, to $133,719 for Q1 FY 2026, compared to $87,091 for Q1 FY 2025[156] - Net earnings for Q4 2025 were $133.719 million, an increase from $87.091 million in Q4 2024, representing a growth of 53.5%[179] - Adjusted net earnings for Q4 2025 were $133.719 million, compared to $82.567 million in Q4 2024, reflecting a year-over-year increase of 61.8%[179] - Adjusted earnings per share for Q4 2025 were $2.17, up from $1.35 in Q4 2024, marking a 60.7% increase[179] - EBITDA for Q4 2025 was $207.832 million, compared to $140.694 million in Q4 2024, indicating a growth of 47.7%[185] - Adjusted EBITDA for Q4 2025 was $207.832 million, up from $134.851 million in Q4 2024, representing a 54.1% increase[185] - EBIT for Q4 2025 was $178.794 million, an increase from $112.818 million in Q4 2024, reflecting a growth of 58.3%[182] Segment Performance - Aerospace segment net sales rose to $634,897, up from $493,882, while Industrial segment net sales increased to $361,557 from $278,843[141] - Aerospace segment net sales increased by $141,015, or 28.6%, to $634,897 for Q1 FY 2026, compared to $493,882 for Q1 FY 2025[157] - Industrial segment net sales increased by $82,714, or 29.7%, to $361,557 for Q1 FY 2026, compared to $278,843 for Q1 FY 2025[162] - Aerospace segment earnings increased by $53,670, or 56.7%, to $148,395 for Q1 FY 2026, compared to $94,725 for Q1 FY 2025[160] - Industrial segment earnings increased by $26,797, or 66.7%, to $66,994 for Q1 FY 2026, compared to $40,197 for Q1 FY 2025[163] Cash Flow and Expenses - Free cash flow for Q1 FY 2026 was $70,308, a significant increase from $942 in Q1 FY 2025, attributed to higher earnings and tax payment timing[144] - Net cash provided by operating activities was $114,437 for Q1 FY 2026, compared to $34,516 for the same period in FY 2025[173] - Net cash used in investing activities increased to $48,329 for Q1 FY 2026, compared to $32,100 for Q1 FY 2025, primarily due to higher capital expenditures[175] - Selling, general, and administrative expenses rose by 36.3% to $94,985, representing 9.5% of net sales, compared to 9.0% in Q1 FY 2025[151] - Research and development costs were $37,756, or 3.8% of net sales, slightly down from 3.9% in Q1 FY 2025[152] Tax and Interest - The effective tax rate for Q1 FY 2026 was 20.9%, up from 14.5% in Q1 FY 2025[141] - The adjusted effective tax rate for Q4 2025 was 20.9%, compared to 14.0% in Q4 2024[180] - Interest expense decreased by $1,997, or 16.2%, to $10,344 for Q1 FY 2026, compared to $12,341 for Q1 FY 2025, with interest expense as a percentage of net sales at 1.0%[153] Operational Changes - The company plans to wind down its on-highway natural gas truck manufacturing operations in China, expecting pre-tax charges of approximately $20,000 to $25,000[139][140] Debt - Net debt borrowings increased to $185,448 in Q1 FY 2026, compared to $40,764 in Q1 FY 2025[176]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________ COMMISSION FILE NUMBER 1-16483 Mondelēz International, Inc. (Exact name of registrant as specified in its charter) (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23999 Manhattan Associates, Inc. (Exact name of registrant as specified in its charter) | Georgia | | | --- | --- | | (State or othe ...

Financial Performance - In Q1 Fiscal 2026, the company reported revenues of $251.2 million, a 4% increase from the previous year, with net income of $41.4 million, or $3.40 per diluted share[105][119]. - Gross profit increased by 20% to $71.4 million, with gross profit margin rising to 28% from 25% year-over-year[116]. - Revenue from the electric utility market rose by 35% to $69.3 million, while revenue from the oil and gas market increased by 2% to $97.9 million[115]. - International revenues increased by 29% to $56.3 million, primarily due to increased activities in the Middle East, Africa, and Asia/Pacific regions[114]. Order and Backlog - The order backlog increased to $1.6 billion as of December 31, 2025, a 14% increase from $1.4 billion at September 30, 2025, with 32% from oil and gas, 30% from electric utility, and 22% from commercial and other industrial markets[120]. - Bookings increased by 63% in Q1 Fiscal 2026 to $438.8 million, compared to $268.6 million in Q1 Fiscal 2025, driven by improved activity in the commercial and other industrial market[121]. Expenses and Cash Flow - Selling, general and administrative expenses rose by 17% to $25.2 million, representing 10% of revenues, up from 9% in the previous year[117]. - Cash, cash equivalents, and short-term investments increased to $500.8 million as of December 31, 2025, from $475.5 million at September 30, 2025[123]. - Operating activities generated net cash of $43.6 million in Q1 Fiscal 2026, compared to $37.1 million in the same period of Fiscal 2025[129]. Strategic Focus - The company is focused on managing product pricing and improving factory efficiencies to mitigate supply chain challenges and rising costs[113]. Accounting and Risk - No material changes to critical accounting policies since the Annual Report for the fiscal year ended September 30, 2025[133]. - No material changes to market risks as of and for the three months ended December 31, 2025, compared to previous reports[134]. - Financial statements prepared in accordance with U.S. GAAP, requiring management estimates and assumptions affecting reported amounts[132].

Exhibit 99.1 MGM Resorts International | | | Three Months Ended | | | | Twelve Months Ended | | | --- | --- | --- | --- | --- | --- | --- | --- | | | December 31, | | December 31, | | December 31, | | December 31, | | | 2025 | | 2024 | | 2025 | | 2024 | | Revenues | | | | | | | | | Casino | $ 2,574,945 | | $ 2,210,746 | | $ 9,450,887 | | $ 8,785,649 | | Rooms | 858,355 | | 942,654 | | 3,377,400 | | 3,681,617 | | Food and beverage | 749,016 | | 751,868 | | 3,045,965 | | 3,078,731 | | Entertainment, retail an ...

Exhibit 99.1 Company / Investor Contact: Tom Wirth EVP & CFO 610-832-7434 tom.wirth@bdnreit.com Brandywine Realty Trust Announces Fourth Quarter, Full Year 2025 Results and Initiates 2026 Guidance Philadelphia, PA, February 3, 2026 - Brandywine Realty Trust (NYSE:BDN) today reported its financial and operating results for the three and twelve-month periods ended December 31, 2025. Management Comments "We achieved many of our full year 2025 business plan objectives including tenant retention, same store NOI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ To _____ Commission File Number: 001-13836 JOHNSON CONTROLS INTERNATIONAL PLC (Exact name of registrant as specified in its charter) One Albert Quay, Cork, Irel ...

Financial Performance - Total sales for 2025 reached £32.7 billion, representing a 4% increase at AER and a 7% increase at CER[6] - Total operating profit surged to £7.9 billion, reflecting a growth of over 100% due to lower legal expenses and higher operating income[6] - Core operating profit increased by 11% to £9.8 billion, driven by growth in Specialty Medicines and Vaccines, alongside improved SG&A productivity[6] - GSK expects 2026 turnover growth between 3% to 5%, with core operating profit and core EPS both anticipated to grow by 7% to 9%[9] - Total turnover for 2025 reached £32,667 million, representing a 4% increase at AER and a 7% increase at CER, with Q4 2025 turnover at £8,618 million, up 6% at AER and 8% at CER[48] - Operating profit for 2025 was £7,932 million, a significant increase of 97% at AER and over 100% at CER, with Q4 2025 operating profit at £1,100 million, up 58% at AER and 65% at CER[63] - Core operating profit for 2025 was £9,783 million, reflecting a 7% increase at AER and an 11% increase at CER, with Q4 2025 core operating profit at £1,634 million, up 14% at AER and 18% at CER[50] - Total earnings per share (EPS) for 2025 was 141.1p, showing a greater than 100% increase, while Q4 2025 EPS was 15.8p, up 56%[69] - Core EPS for 2025 was 172.0p, an 8% increase, with Q4 2025 Core EPS at 25.5p, up 10%[69] Sales Growth by Segment - Specialty Medicines sales grew to £13.5 billion, up 17%, with significant contributions from Oncology (+43%) and Respiratory, Immunology & Inflammation (+18%)[6] - Respiratory, Immunology & Inflammation sales reached £3,810 million in 2025, growing by 15% year-over-year and 18% in Q4 2025, driven by Nucala and Benlysta[23] - Nucala sales grew at a double-digit rate globally, with US sales accelerating in Q4 2025 following its recent launch in COPD, despite ongoing pricing pressures[24] - Benlysta sales totaled £1,773 million in 2025, reflecting a 19% increase year-over-year and a 22% increase in Q4 2025, driven by strong demand and volume growth[25] - Oncology sales reached £1,977 million in 2025, with a 40% year-over-year growth, primarily driven by Jemperli and Ojjaara/Omjjara[26] - Jemperli sales grew to £861 million in 2025, marking an 84% increase year-over-year, supported by FDA and EMA approvals expanding its indication[27] - Vaccines sales totaled £9,157 million in 2025, with a 2% increase year-over-year, driven by strong demand for Shingrix and Meningitis vaccines[30] - Shingrix sales grew by 42% in Europe for the year, reflecting strong uptake and expanded public funding across several countries[31] - US sales of Shingrix decreased by 17% in 2025 due to challenges in activating unvaccinated consumers, with a cumulative immunization rate of 44%[33] - General Medicines sales were £10,036 million in 2025, reflecting a 4% decline year-over-year, with Trelegy sales growing by 11%[37] Research and Development - Research and development expenses totaled £7,525 million for 2025, an 18% increase at AER and 19% at CER, with Q4 2025 R&D expenses at £2,350 million, up 16% at AER and 17% at CER[55] - Five major FDA approvals were achieved in 2025, including Blenrep and Nucala for COPD, enhancing the product pipeline[10] - GSK has submitted regulatory applications for multiple products, including bepirovirsen for chronic hepatitis B in the US, EU, CN, and JP[89] - Anticipated pipeline milestones include regulatory decisions for depemokimab in H1 2026, indicating ongoing investment in R&D[88] - GSK completed the acquisition of IDRx, Inc. for a total consideration of US$1.1 billion (£840 million) and potential additional payments of up to US$150 million (£119 million) based on regulatory milestones[194] - GSK acquired BP Asset IX, Inc. for US$1.2 billion (£906 million) with additional success-based regulatory milestone payments of up to US$800 million (£588 million)[195] Shareholder Returns and Financial Management - GSK has initiated a £2 billion share buyback program, with £1.4 billion executed to date[14] - The company declared a dividend of 18p for Q4 2025 and expects to increase it to 70p for the full year 2026[13] - Cash generated from operations for 2025 was £8,943 million, an increase from £7,861 million in 2024, with Q4 2025 cash generation at £2,689 million[73] - Free cash inflow for 2025 was £4,029 million, a 41% increase from £2,863 million in 2024, with Q4 2025 free cash inflow at £960 million[77] - Dividends paid to shareholders increased to £2,564 million in 2025 from £2,444 million in 2024, a rise of 4.9%[141] Legal and Regulatory Matters - The effective tax rate for total results was 15.0% for 2025, while the core tax rate was 17.1%[66] - The Group's aggregate provision for legal and other disputes was £210 million as of 31 December 2025, a decrease from £1,446 million in 2024[160] - Significant legal charges and divestments included £367 million ($500 million) from settlements related to mRNA patent issues[123] Corporate Social Responsibility and Sustainability - GSK's commitment to responsible business includes making vaccines and medicines available at sustainable prices, with a focus on underserved populations[92] - GSK has pledged £6 million to the Global Fund to strengthen community-led responses to HIV, tuberculosis, and malaria, matched by the Gates Foundation for a total of £12 million[96] - GSK retained its position on the CDP 2025 A List for Climate Change and Water, ranking in the top 4% of companies assessed[96] - GSK's commitment to a net zero, nature-positive planet includes ambitious goals set for 2030 and 2045[92] Financial Position and Assets - Total assets increased to £61,118 million in 2025, up from £59,463 million in 2024, representing a growth of 2.8%[138] - Total equity increased to £15,956 million in 2025, up from £13,086 million in 2024, representing a growth of 21.6%[138] - Cash and cash equivalents at the end of 2025 were £3,397 million, down from £3,870 million at the end of 2024, a decrease of 12.2%[142] - The net surplus on the Group's pension plans improved to £229 million at 31 December 2025 from a net deficit of £103 million at 31 December 2024[188] Market Position and Future Outlook - GSK's 2031 sales outlook is projected to exceed £40 billion, supported by ongoing R&D investments and product launches[10] - The company plans to continue expanding its product offerings and market presence, focusing on innovative therapies and strategic acquisitions[143]